Compare Meta Platforms Inc (META) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Natera Inc. Common Stock — how do they compare? Meta Platforms Inc trades at $727.3 (market cap $1.94T), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Meta Platforms Inc is far larger — about 34× Natera Inc. Common Stock's market cap, and Meta Platforms Inc pays a 0.28% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 128 Days and Natera Inc. Common Stock for 0 Days on average.
| META | NTRA | |
|---|---|---|
Market Cap | $1.94T | $57.03B |
Volume | 22,627,792 | 1,131,157 |
Sector | Media | Health |
52-Week High | $777.59 | $425.64 |
52-Week Low | $525.72 | $179.42 |
Typical Hold Time | 128 Days | 0 Days |
Enterprise Value | $1.96T | $56.18B |
Dividend Yield | 0.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $762.50, up 2.63% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $201B revenue in 2025, 29.84% net margin, and consistent earnings beats in recent quarters. Recent AI developments including Muse Spark launch and institutional buying activity support positive momentum.
Outlook remains positive with 81% analyst buy ratings and $802.80 consensus target, though risks include regulatory lawsuits and high capital expenditures. The stock trades near resistance at $765 with strong institutional support, positioning it for potential upside if AI monetization accelerates.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
